지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수12
Ⅰ. 서론1. 연구의 필요성 ··········································································· 12. 연구의 목적 ············································································· 33. 용어의 정의 ············································································· 3Ⅱ. 문헌고찰1. 척추마취시 생리학적 변화 및 부작용 ··············································· 52. 척추마취시 고비중 Bupivacaine의 마취효과 ······································· 73. 척추마취와 체위와의 관계 ···························································· 7III. 연구방법1. 연구 설계 ·············································································· 82. 연구기간 및 대상······································································· 83. 연구 도구················································································ 94. 자료수집 및 연구절차································································· 105. 자료 분석 방법········································································· 11IV. 연구결과1. 대상자의 일반적 및 수술관련 특성에 대한 동질성 검증 ······················· 112. 고비중 bupivacaine 척추마취 후 체위에 따른 마취수준의 비교················ 123. 고비중 bupivacaine 척추마취 후 체위에 따른 수축기 혈압의 비교············ 124. 고비중 bupivacaine 척추마취 후 체위에 따른 이완기 혈압의 비교············ 125. 고비중 bupivacaine 척추마취 후 체위에 따른 심박동수의 비교················ 136. 고비중 bupivacaine 척추마취 후 체위에 따른 산소포화도의 비교·········· 137. 고비중 bupivacaine 척추마취 후 체위에 따른 호흡곤란 호소, Ephedrine과 Atropine 투여 횟수 비교··························································· 138. 고비중 척추마취 후 체위에 따른 오심 및 구토 빈도 차이 비교············· 14V. 논의 ····················································································· 24VI. 결론 및 제언··········································································· 28참고문헌····················································································· 31Abstract ···················································································· 35부록 ························································································· 38
0